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Table 1: Patients characteristics 
Patient (Family) 1 (F1) 2 (F2) 3 (II-3 F3) 4 (III-1 F3) 
Age (onset/present) 25/50 18/25 3/42 NN/7 
First sign Deafness Suicide Dystonia Dev. delay 
Cognitive decline + + + + 
Cerebellar ataxia  + - - + 
Psychiatric signs - + - - 
Deafness + - - - 
Pyramidal Syndrome - - + - 
Seizures, myoclonia - - - + 
Dystonia - - + - 
Muscle weakness + - - - 
MRI Cerebellar A + - + + 
Cortical A - + - - 
Brainstem A + - - - 
Striatum HS - + + - 
White matter HS - - - + 
EMG + NCV Myogenic Axonal Axonal NA 
Lactatemia 5.3 (45 y) 3.7 (23 y) 1.7 (39 y) 1.6 (3 y) 
Lactatorrachia NA High (MRS) 4.4 (39y) N (MRS) 
Muscle Histology SDH++/COX- COX- COX- Low COX 
Age is indicated in years: first number is the patient’s age at onset; second number is the 
patient’s age at diagnosis or at death (Patient 1); + = present; - = absent; A=Atrophy; Axonal 
= axonal sensorimotor polyneuropathy; COX-=presence of scattered cytochrome c oxidase 
(COX) negative fibers; Dev. Delay Development Delay; EMG + NCV = electromyography 
with measurement of Nerve Conduction Velocities; High = values above highest normal 
values; HS=hypersignals on brain MRI; Low COX= low histochemical cytochrome c oxidase 
reaction. Lactatemia and lactatorrachia: the level of lactate is indicated as mM with the age at 
measurement in years (y) indicated between brackets; N=normal values; NA =data non 
available; NMR: nuclear Magnetic Resonance. 
 
Table 2: Spectrophotometric assays of OXPHOS in the muscle of the patients with the m.1644G>A 
mutation 
 
Patient 1 
(control values) 
Patient 2 
(control values) 
Patient 3 
(control values) 
Patient 4 
(control values) 
CI 14 (22±7) 4
*
(59±32) 7 (42±15) 84 (60-123) 
CII 78
*
(31±8) 74 (78±38) 64 (61±20) 151 (105-270) 
CIII 170
*
 (107±26) 224(242±132) 210 (162±67) 1401 (1007-2465) 
CIV 70 (56±17) 20
*
(201±99) 47
*
 (193±61) 
254 (175-385) ‡ 
1598 (1100-2800) 
II+III 40
*
 (18±7) 69 (76±46) 42 (50±16) 367 (202-525) 
CS 563
*
 (153±35) 195 (215±110) 172 (216±70) 100 (70-150) ‡ 
CI/CS 
CII/CS 
CIII/CS 
CIV/CS 
0.02
*
 (0.15±0.04) 
0.14 (0.21±0.06) 
0.30
*
 (0.72±0.20) 
0.12
*
 (0.37±0.11) 
0.02
*
 (0.28±0.08) 
0.38 (0.38±0.10) 
1.15 (1.18±0.45) 
0.10
*
 (1.40±0.40) 
0.04
*
 (0.20±0.05) 
0.37 (0.29±0.07) 
1.22 (0.78±0.22) 
0.27
*
 (0.94±0.24) 
- 
- 
- 
- 
Spectrophotometric assays of respiratory chain activities are expressed as nanomoles per 
minute and mg protein. They were performed on muscle homogenates for Patients 1, 2 and 3 
and on isolated muscle mitochondria for Patient 4 with the exception of the two assays 
marked with ‡ that were performed on muscle homogenates. Each patient has been analyzed 
with different assay protocols, the results have therefore to be compared to their own set of 
control values expressed as mean±standard deviation (Patients 1, 2 and 3) or as normal range 
(Patient 4). Numbers marked with 
* 
are significantly abnormal. CI=respiratory complex I 
(rotenone sensitive NADH ubiquinone oxido-reductase) activity; CII= respiratory complex II 
(succinate ubiquinone oxido-reductase) activity; CIII= respiratory complex III (antimycin 
sensitive ubiquinol cytochrome c oxido-reductase) activity; CIV= respiratory complex IV 
(cytochrome c oxidase) activity; II+III=combined respiratory complex II and III (succinate 
cytochrome c oxido-reductase) activity; CS=citrate synthase, a Krebs cycle enzyme, activity.  
Table 3: Combined respiratory chain defect was observed in the cultured skin 
fibroblasts and in cybrids with the m.1644G>A mutation  
 Patient 2 Patient 3 Patient 4 Control 
fibroblasts 
Mutant 
cybrids 
Control 
cybrids 
VO2 (succ) 
VO2 (pyr) 
ratio 
10.6 
3.3 
3.11
*
 
11.3 
4.5 
2.51
*
 
11.0 
4.31 
2.55
*
 
11.5±3.2 
7.3±2.5 
1.63±0.55 
6.6
*
 
2.9
*
 
2.27
*
 
12.9±4.1 
9.7±3.8 
1.50±0.63 
CII 31 36 34 26±8 49 43±19 
CIII 28 80 30 55±17 50 47±12 
CIV 24
*
 38
*
 42
*
 83±16 13
*
 71±18 
II+III 26 35 35 31±7 62 50±21 
CS 68 92 72 77±19 238
*
 115±28 
CII/CS 
CIII/CS 
CIV/CS 
0.46 
0.41 
0.35
*
 
0.39 
0.87 
0.41
*
 
0.47 
0.42 
0.58
*
 
0.37±0.10 
0.79±0.25 
1.11±0.22 
0.21 
0.21 
0.05
*
 
0.39±0.17 
0.41±0.11 
0.63±0.19 
All values are expressed as expressed as nanomoles per minute and mg protein. Mutant 
cybrids had 100% m.1644G>A mutation. VO2 (succ)]: respiration with succinate that enters 
the respiratory chain at complex II; VO2 (pyr): respiration with pyruvate that enters the 
respiratory chain at complex I; ratio: ratio between the respiration rates on these two 
substrates; CII= respiratory complex II (succinate ubiquinone oxido-reductase) activity; CIII= 
respiratory complex III (antimycin sensitive ubiquinol cytochrome c oxido-reductase) 
activity; CIV= respiratory complex IV (cytochrome c oxidase) activity; II+III=combined 
respiratory complex II and III (succinate cytochrome c oxido-reductase) activity; CS=citrate 
synthase, a Krebs cycle enzyme, activity; control values are expressed as 
mean±standarddeviation of 52 analyses for fibroblasts and 14 for cybrids; Numbers marked 
with 
* 
are significantly abnormal.
Table 4: Homogeneous distribution of the m.1644G>A mutation in the patients’ 
different tissues  
 muscle blood Buccal C Urinary S Nasal C Fibros 
Patient1 92%      
Patient2 100% 100%    100% 
Patient 3 (II-3) 100%  98% 98% 100% 100% 
Patient 4 (III-1) 61% 63% 66% 74%  66% 
Pt3 mother (I-1)  64% 54% 65% 64%  
Pt3 sister (II-1)  65% 68% 79%   
Pt3 sister (II-5)  56% 52% 47%   
Proportion of the mutation evaluated with fluorescent PCR-restriction. Buccal C=DNA 
extracted from buccal mucosa; Urinary S=DNA extracted from the urinary sediment; Nasal 
C=DNA extracted from nasal mucosa; fibros=DNA extracted from cultured skin fibroblasts. 
